Publicaciones en colaboración con investigadores/as de University of Lille Nord de France (61)

2024

  1. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial

    Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257

  2. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  2. Hepatic p63 regulates glucose metabolism by repressing SIRT1

    Gut, Vol. 72, Núm. 3, pp. 472-483

  3. Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

    Annals of Oncology

2022

  1. Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818

  2. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  3. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

  4. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort

    Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735

  5. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

  6. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310

2021

  1. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 2, pp. 324-333

  2. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  5. Identification of sex-specific biomarkers predicting new-onset heart failure

    ESC Heart Failure, Vol. 8, Núm. 5, pp. 3512-3520

  6. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

    American Journal of Hematology, Vol. 96, Núm. 1, pp. 69-79

  7. Integrated Multiomics Reveals Glucose Use Reprogramming and Identifies a Novel Hexokinase in Alcoholic Hepatitis

    Gastroenterology, Vol. 160, Núm. 5, pp. 1725-1740.e2

  8. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  9. Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis

    Journal of Hepatology, Vol. 75, Núm. 4, pp. 912-923